文献速递心力衰竭与心肌病

非奈利酮对射血分数轻度降低或保留心衰门诊恶化事件的影响:FINEARTS-HF 二次分析

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-02-26

本研究为 FINEARTS-HF 随机临床试验的二次分析,纳入 6001 例射血分数≥40%的心衰患者,评估非奈利酮对需口服利尿剂强化的门诊恶化心衰事件的影响。结果显示,门诊口服利尿剂强化事件常见且与预后不良相关,非奈利酮可降低该事件风险(HR 0.89,95%CI 0.80-0.98;

要点

  • 门诊口服利尿剂强化事件常见,且与全因死亡风险升高相关。
  • 非奈利酮降低门诊口服利尿剂强化事件风险(HR 0.89)。
  • 非奈利酮降低扩展复合终点风险(HR 0.85)。

核心结论

  • 在射血分数轻度降低或保留的心衰患者中,需口服利尿剂强化的门诊恶化心衰事件常见、与不良预后相关,且非奈利酮可减少此类事件。

研究设计与样本

  • FINEARTS-HF 随机临床试验的二次分析,全球多中心,纳入 6001 例射血分数≥40%的心衰患者,随机 1:1 接受非奈利酮或安慰剂。

主要发现

  • 首次恶化心衰事件包括 664 例心衰住院、87 例紧急心衰就诊和 1250 例口服利尿剂强化。
  • 心衰住院后死亡率为 27.7(95%CI 24.3-31.5)/100 患者年,紧急心衰就诊后为 13.6(95%CI 8.8-21.1)/100 患者年,门诊口服利尿剂强化后为 11.6(95%CI 10.2-13.1)/100 患者年,无恶化心衰者为 4.5(95%CI 4.2-4.9)/100 患者年。
  • 将门诊口服利尿剂强化加入主要终点后,发生事件的患者数从 1343 增至 2238。

临床怎么用

  • 对射血分数轻度降低或保留的心衰患者,应关注门诊口服利尿剂强化事件,并将其视为预后不良的标志。
  • 非奈利酮可用于减少此类患者门诊恶化心衰事件的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening HF events in patients with mildly reduced or preserved ejection fraction is unknown. OBJECTIVE: To evaluate the effect of finerenone on outpatient worsening HF events requiring oral diuretic intensification among patients with HF with mildly reduced or preserved ejection fraction. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF), a global, multicenter randomized clinical trial. Patients had HF and an ejection fraction of 40% or greater. Data analysis was conducted from September 1 to December 10, 2024. INTERVENTION: Participants were randomized 1:1 to finerenone or placebo. MAIN OUTCOMES AND MEASURES: Primary outcome events (cardiovascular death, HF hospitalization, and outpatient urgent HF visit requiring intravenous diuretic therapy) were centrally adjudicated. In this prespecified analysis, outpatient oral diuretic intensification events were defined as initiations of loop or thiazide diuretic or increases in loop diuretic dosage. The risk of all-cause death following each type of worsening HF event (HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification) and the effect of finerenone on outpatient oral diuretic intensification alone or as part of an extended composite outcome with primary outcome events were evaluated. RESULTS: A total of 6001 participants (mean [SD] age, 72.0 [9.6] years; 2732 [46%] female) were enrolled. First worsening HF events included 664 HF hospitalizations, 87 urgent HF visits, and 1250 oral diuretic intensifications. Rates of death were higher following worsening HF: 27.7 (95% CI, 24.3-31.5) per 100 patient-years after HF hospitalization, 13.6 (95% CI, 8.8-21.1) per 100 patient-years after urgent HF visit, and 11.6 (95% CI, 10.2-13.1) per 100 patient-years after outpatient oral diuretic intensification compared with 4.5 (95% CI, 4.2-4.9) per 100 patient-years for patients without worsening HF. Adding outpatient oral diuretic intensification to the primary outcome increased the number of patients experiencing events from 1343 to 2238. Finerenone reduced outpatient oral diuretic intensification alone (hazard ratio [HR], 0.89 [95% CI, 0.80-0.98]; P = .02) and in an extended composite outcome that further included cardiovascular death, HF hospitalization, and urgent HF visit (HR, 0.85 [95% CI, 0.78-0.92]; P < .001). CONCLUSIONS AND RELEVANCE: Outpatient worsening HF events requiring oral diuretic intensification were common, associated with poor prognosis, and reduced by finerenone in patients with HF with mildly reduced or preserved ejection fraction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Cunningham, Chatur, Claggett, et al. Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40009358. doi:10.1001/jamacardio.2025.0016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。